10月15日，百济神州盘中上涨5.05%，报369.175美元/股，成交额4394.53万美元。
当日催化来自创新药板块整体走强。盘中港股创新药概念同步活跃，百济神州港股一度涨超4%，机构认为中国医疗保健板块处于周期底部，管线进展有望提振情绪，中国创新资产在肺癌及肿瘤学大会上持续受关注。
同时，机构配置意愿亦有支撑。10月14日披露显示，摩根大通对百济神州H股持股比例由9.89%升至10.01%；此前公司上半年收入32.19亿美元，同比增长32.3%，净利润4.64亿美元，同比增长385.8%。
百济神州有限公司的主营业务是研究、开发、生产以及商业化创新型药物。公司的主要产品是抗肿瘤类药物。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.